Stock Fundamentals

Company Information

Company Name
Alx Oncology Holdings 
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US00166B1052
CIK: 0001810182
CUSIP: 00166B105
Currency: USD
Full Time Employees: 43
Phone: 650 466 7125
Fiscal Year End: December
IPO Date: Jul 17, 2020
Description:

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Address:

323 Allerton Avenue, South San Francisco, CA, United States, 94080

Directors & Officers

Name Title Year Born
Mr. Jason W. Lettmann CEO & Director 1977
Mr. Harish Shantharam C.F.A. Chief Financial Officer 1981
Ms. Shelly Wong CPA Senior VP of Finance & Chief Accounting Officer 1977
Dr. Barbara J. Klencke M.D. Chief Medical Officer 1957
Mr. Jeff E. Knight M.P.H. Chief Development & Operating Officer 1972
Dr. Athanasios Tsiatis M.D. Senior Vice President of Clinical Development NA
Dr. Lin Yeong-Liang M.D., M.S. Senior Vice President of Drug Safety & Pharmacovigilance NA
Ms. Lisa Sauer Senior Vice President of Regulatory Affairs & Quality Assurance NA
Ms. Sue Naim Senior Vice President of Clinical Operations NA
Ms. Venita De Almeida Ph.D. VP & Head of Research Program Development NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Mar 19, 2026 Jason Lettmann N/A Sale 12.31K $2.17 $26.71K
Mar 19, 2026 Shelly Pinto N/A Sale 903.00 $2.17 $1.96K
Feb 02, 2026 Corey S Goodman N/A Purchase 3.18M $1.57 $5.00M
Jan 06, 2026 Shelly Pinto N/A Sale 3.93K $1.11 $4.36K
Sep 17, 2025 Jason Lettmann N/A Purchase 71.16K $1.08 $76.86K
Sep 16, 2025 Jason Lettmann N/A Purchase 21.07K $1.07 $22.54K
Jul 07, 2025 Shelly Pinto N/A Sale 2.01K $0.45 $904.95
Jun 30, 2025 Shelly Pinto N/A Sale 1.53K $0.43 $658.76

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
RA Capital Management, LLC 13.01M Mar 31, 2026 9.67% $0.28 0.00%
TCG Crossover Management, LLC 13.01M Mar 31, 2026 9.67% $0.75 0.00%
venBio Partners LLC 12.88M Mar 31, 2026 9.58% $9.21 32.83%
Redmile Group, LLC 7.96M Mar 31, 2026 5.92% $1.06 143.95%
Blackstone Inc 5.83M Mar 31, 2026 4.33% $0.05 0.00%
Driehaus Capital Management LLC 5.73M Mar 31, 2026 4.26% $0.08 303.03%
Vanguard Capital Management, LLC 4.18M Mar 31, 2026 3.11% $0.00 0.00%
Marshall Wace Asset Management Ltd 3.76M Mar 31, 2026 2.79% $0.01 14,144.83%
Vivo Capital, LLC 3.18M Mar 31, 2026 2.37% $0.53 0.00%
5AM Venture Management, LLC 3.06M Mar 31, 2026 2.27% $1.70 0.00%
Orbimed Advisors, LLC 2.87M Mar 31, 2026 2.13% $0.11 0.00%
Almitas Capital LLC 2.54M Dec 31, 2025 1.89% $0.63 -50.00%
Adage Capital Partners Gp LLC 2.00M Mar 31, 2026 1.49% $0.01 0.00%
Millennium Management LLC 1.99M Mar 31, 2026 1.48% $0.00 -37.95%
Vanguard Group Inc 1.63M Dec 31, 2025 1.21% $0.00 6.69%
Two Sigma Investments LLC 1.59M Mar 31, 2026 1.18% $0.00 148.02%
Squadron Capital Management LLC 1.46M Mar 31, 2026 1.09% $1.07 0.00%
Susquehanna International Group, LLP 1.33M Mar 31, 2026 0.99% $0.00 779.91%
Acadian Asset Management LLC 1.10M Mar 31, 2026 0.82% $0.00 0.00%
Ensign Peak Advisors Inc 950.55K Mar 31, 2026 0.71% $0.00 0.00%

Shares Statistics

Shares Outstanding: 134.56M
Shares Float: 107.02M
% Insiders: 92.00%
% Institutions: 7,877.10%
Short % Float: 1.41%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 HBM Healthcare Investments AG Ord 8.59M 6.38% ▲ 80.13% Mar 31, 2026
2 Vanguard Total Stock Mkt Idx Inv 3.64M 2.71% ▲ 0.00% Apr 30, 2026
3 Biotech Growth Ord 694.70K 0.52% ▼ 25.00% Feb 28, 2026
4 Vanguard Institutional Extnd Mkt Idx Tr 400.72K 0.30% ▲ 0.00% Apr 30, 2026
5 Fidelity Extended Market Index 187.91K 0.14% ▼ 3.07% Apr 30, 2026
6 Vanguard Health Care ETF 97.52K 0.07% ▼ 0.37% Apr 30, 2026
7 Vanguard Instl Ttl Stck Mkt Index Trust 96.73K 0.07% ▼ 19.61% Apr 30, 2026
8 Fidelity Nasdaq Composite Index 88.96K 0.07% ▲ 0.00% Apr 30, 2026
9 Datamira LS World Fund F EUR Acc 82.90K 0.06% ▲ 0.00% May 31, 2026
10 Fidelity Total Market Index 77.67K 0.06% ▲ 0.00% Apr 30, 2026

Valuation Metrics

Enterprise Value: $83.49M
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $212.61M
EBITDA: $-87.35M
Book Value: $1.13
Earnings/Share: $-1.49
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -36.76%
ROE (TTM): -74.17%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -100.00%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 2.07x 0.38x 0.56x -64.93x -0.10x
2024-12-31 7.26x 0.10x 0.23x -82.40x -0.09x
2023-12-31 5.24x 0.06x 0.22x -108.80x -0.07x
2022-12-31 9.57x 0.04x 0.14x -29.23x -0.08x
2021-12-31 24.00x 0.00x 0.05x -6,427.31x -0.01x
2020-12-31 70.28x 0.00x 0.01x -53.84x 0.00x
2019-12-31 1.97x -19.64x 1.03x -913.48x -0.29x
2018-12-31 5.45x 0.00x 0.18x N/A 0.00x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ALXO.US!